Trade Bristol Myers ^BMY

USA Financial Formulas Makes New $919,000 Investment in Bristol Myers Squibb Company $BMY - Markets Daily

13,923 Shares in Bristol Myers Squibb Company $BMY Bought by USA Financial Formulas - Zolmax

Lupin Receives CDSCO Approval for Nivolumab Biosimilar in India, ETPharma

Birch Hill Investment Advisors LLC Acquires 160,411 Shares of Bristol Myers Squibb Company $BMY

Bristol Myers Squibb Company $BMY Shares Newly Purchased by New England Research & Management Inc.

Bristol Myers Squibb (NYSE:BMY) Stock Moved Up to "Strong-Buy" by The Goldman Sachs Group

Bristol Myers Squibb Company $BMY Stock Bought by Howard Capital Management LLC - Daily Political

Analysts Conflicted on These Healthcare Names: Perspective Therapeutics (CATX), Bristol-Myers Squibb (BMY) and Incyte (INCY)

RBC Capital Sticks to Its Buy Rating for Roche Holding AG (RHHVF)

Eli Lilly & Co (LLY) Receives a Buy from RBC Capital

RBC Capital Sticks to Their Hold Rating for Merck & Company (MRK)

RBC Capital Reaffirms Their Hold Rating on Pfizer (PFE)

Bristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know

Bristol Myers Squibb's Rally Has Momentum, but Can Its New Drugs Justify More Upside?

Triasima Portfolio Management inc. Purchases New Stake in Bristol Myers Squibb Company $BMY

Iams Wealth Management LLC Acquires 24,964 Shares of Bristol Myers Squibb Company $BMY

How Mixed Admilparant Results and Strong Oncology Data Will Impact Bristol Myers Squibb (BMY) Investors

Insitro's Virtual Human attracts $1.5B MASH deal with Astrazeneca

Bristol Myers Squibb Company $BMY Stock Sold by Chiron Capital Management LLC - Stock Observer

Bristol Myers Squibb Company $BMY Shares Sold by Viking Fund Management LLC

Bristol Myers Squibb Company $BMY Position Reduced by Fort Washington Investment Advisors Inc. OH

Head-To-Head Analysis: Milestone Pharmaceuticals (NASDAQ:MIST) & Bristol Myers Squibb (NYSE:BMY) - Markets Daily

65,007 Shares in Bristol Myers Squibb Company $BMY Purchased by B.A. Schrock Wealth Management Inc. - Stock Observer

14,607 Shares in Bristol Myers Squibb Company $BMY Acquired by Sanders Morris Harris LLC - Daily Political

Stock Market Movers: Best and Worst Performers of 14 October 2026

Bristol Myers Squibb (NYSE:BMY) Shares Up 4% - What's Next?

Bristol Myers Squibb Company $BMY Shares Sold by Perpetual Ltd

Bristol-Myers Squibb Company Stock Live Price, Chart, Analysis, News & Forecast - Buy, Sell & Trade US Equities Today

Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial

Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer: a randomized phase 2 trial

Renal Cancer Clinical Trial Pipeline Gains Momentum: 75+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight | ABNewswire

Bristol Myers Squibb Company $BMY Shares Sold by Courier Capital LLC - Zolmax

Bristol Myers Squibb (BMY) Stock Trades At A Discount Following Its 38% Run

BlackLine Honors Global Enterprise Leaders Transforming Financial Operations

Bristol Myers Squibb (BMY) Stock May Be Undervalued Despite Fresh Phase 3 Trial Wins

Bristol Myers Squibb (NYSE:BMY) Stock Price Target Cut by Wells Fargo & Company - Daily Political

Pulmonary Fibrosis Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 110+ Leading Players Wheeling the Therapeutics Landscape | ABNewswire

Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Bristol-Myers Squibb (BMY) and Palvella Therapeutics (PVLA)

Health Care Up Amid Deal Activity - Health Care Roundup | Morningstar

BMY's RYZ101 Meets Phase 3 Goal, Improving PFS In Advanced GEP-NETs

Bristol Myers dips on 'confounding' lung drug results

13 New 4-Star Stocks This Week | Morningstar

Bristol Myers Squibb Reports Positive Phase 3 Results For Admilparant In IPF

Bristol-Myers Squibb Announces Positive Topline Data From RYZ101 Study, Stock Up In Pre-Market

Bristol Myers' Phase 3 Trial Of Admilparant In Idiopathic Pulmonary Fibrosis Met Primary Endpoint

Bristol Myers Squibb Treatment Meets Primary Endpoint in Phase 3 Trial for Idiopathic Pulmonary Fibrosis | Morningstar

Bristol Myers Squibb stock surges on dual phase 3 clinical trial successes

Bristol Myers cancer therapy meets main goal in late-stage study

Bristol Myers Squibb (NYSE:BMY) and Takeda Pharmaceutical (NYSE:TAK) Financial Review - Zolmax

Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint | Morningstar

NSCLC Pipeline 2026: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | AbbVie, Xcovery, Sanofi, Pfizer, Mirati Therapeutics, AstraZeneca, Daiichi Sankyo, Merck | ABNewswire

Bristol Myers Squibb (NYSE:BMY) Stock Gets Price Target Trim from Cantor Fitzgerald - Stock Observer

Bristol Myers Squibb Company $BMY Holdings Lessened by RTD Financial Advisors Inc. - Markets Daily

20,370 Bristol Myers Squibb Company $BMY Shares Bought by Apella Capital LLC

Bristol Myers Squibb Company $BMY Shares Sold by RTD Financial Advisors Inc. - Stock Observer

Bank of America Cuts Bristol Myers Squibb (NYSE:BMY) Price Target to $66.00

Bristol Myers Squibb (NYSE:BMY) Stock Price Target Raised at Rothschild & Co Redburn

53,744 Bristol Myers Squibb Company $BMY Shares Sold by Douglas Lane & Associates LLC

Bristol Myers Squibb (NYSE:BMY) Stock Price Target Lowered at Bank of America - Daily Political

Bristol Myers Squibb Company $BMY Stock Bought by Monument Capital Management

Bristol Myers Squibb Company $BMY Shares Acquired by Mn Services Vermogensbeheer B.V.

11,617 Bristol Myers Squibb Company $BMY Shares Bought by Monument Capital Management - Stock Observer

Quintet Private Bank Europe S.A. Lowers Holdings in Bristol Myers Squibb Company $BMY - Markets Daily

Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?

Bristol Myers Squibb Company $BMY Stock Sold by Quintet Private Bank Europe S.A. - Stock Observer

Bristol Myers Squibb (NYSE:BMY) Stock Price Target Lowered at Cantor Fitzgerald - Markets Daily

BMY Maintains Rating by Morgan Stanley -- Price Target Raised to

5 Dividend Stocks With Fortress-Like Coverage and Room for Things to Go Wrong

Bristol Myers Squibb (BMY) Expands CAMZYOS Approval, Is The Stock Still A Bargain?

Takeda's zasocitinib raises bar for oral psoriasis drugs

Bristol Myers Squibb (NYSE:BMY) Stock Rating Cut to Market Perform at Leerink Partners - Markets Daily

Bristol Myers (BMY) Stock is Trading Below 10 Times Forward Earnings. Here's Why it Matters - Insider Monkey

Top Pharmaceutical Stocks To Follow Now - October 5th - Markets Daily

Top Pharmaceutical Stocks To Follow Now - October 5th - Stock Observer

Pfizer's Turnaround Could Be Bigger Than Investors Think, Set For 20% Upside

Bristol Myers Squibb Deepens Commitment to Healthcare

AbbVie (ABBV) vs Bristol Myers (BMY): Which is a Better Stock to Buy?

CX Institutional Sells 208,135 Shares of Bristol Myers Squibb Company $BMY

Eli Lilly & Co (LLY) Gets a Buy from RBC Capital

BMY Stock Gets Stronger EPS Forecast from Zacks Research - Daily Political

Urine cell-free RNA for bladder cancer detection and treatment response prediction

Analysts unshaken by patient death in BMS lung fibrosis trial

BMY: Legacy Drug Erosion Looms, Oncology Platforms And AI Hold The Upside

RBC Capital Keeps Their Hold Rating on Merck & Company (MRK)

What is Johnson & Johnson's (JNJ) Economic Moat, and is it Widening or Narrowing?

Heparin-Induced Thrombocytopenia Market: Steady Growth Driven by Emerging Non-Heparin Anticoagulants and Novel Therapies by 2034 | ABNewswire

"There is growing emphasis on B-cell maturation antigen-targeted cell therapies to treat Multiple Myeloma"

Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

Bristol Myers Squibb Says FDA Approves Heart Disease Treatment Camzyos for Pediatric Patients | Morningstar

Promising Pharmaceutical Stocks Worth Watching - September 30th

Bristol Myers Squibb's Dividend Sustainability Hinges on One Critical Cash Flow Metric - 24/7 Wall St.

BMY: Growth Portfolio Carries The Case, Patent Cliffs Still Set The Limits

How Strong Phase 3 MRD Data for ZENBEXUS in Myeloma Could Impact Bristol Myers Squibb (BMY) Investors

Heart Failure Clinical Trial Drug Development Pipeline Expands with Contributions from 70+ Key Companies | DelveInsight | ABNewswire

Sugar-rich foods exacerbate antibiotic-induced microbiome disruption

Adrenocortical Carcinoma Market Poised for Sustained Growth Amid Advancements in Treatment and Clinical Innovation by 2036- DelveInsight | Orphagen Pharma, Corcept Therapeutics, Cytovation, Merck | ABNewswire

Bristol Myers Squibb (BMY) Reported 41.1% MRD Negative Responses In Phase 3 Trial

US Economy on Stagflation Watch: Apollo Global Management's Outlook

AI Podcast: Fresh Insights on Fed Rate Cut Timing - News in a New Way

S&P 500 Earnings Season to Test Rally Amidst Dim Outlook

Week ahead: Magnificent 7 earnings, 2 key inflation reports

Week ahead: Earnings bonanza, ECB decision & US inflation

Week ahead: Megacap tech and 1-in-3 Dow components set to report

Week ahead: Fed to hike 100bps into a recession?

Trump's Sudden Russia Policy Shift: Rubio's Influence and Implications

Global Market Review: Gold Volatility and Tech Stock Surge Amidst Economic Uncertainty

September CPI Data: Inflation Hurdles, Tariff Impacts, and Fed Rate Cut Expectations

Navigating the AI Boom: Strategies for Investors Amid Nvidia's Valuation Surge

Fund Managers Cautious in Q4: AI, Inflation, and Monetary Policy in Focus

US Government Shutdown Threatens October Inflation Data Release

US-EU Relations: Russia Sanctions Unite Despite Trade Tensions

BOJ Warns of Japan Stock Market Overheating, U.S. Trade Policy Risk